Panel Discussion: From Exploratory Signal to Regulatory Confidence: Building the Evidence Base for MRD as an Approved Endpoint
- Outlining the evidence regulators expect for ctDNA endpoint consideration, including how multiple myeloma secured its first approval
- Identifying gaps between exploratory biomarker use and surrogate endpoint qualification
- Positioning ctDNA endpoints for inclusion in regulatory dialogue and submission packages